Prophylaxis of fungal infections in transplant patients

Abdala, Edson; Costa, Sílvia Figueiredo; Strabelli, Tânia Mara Varejão; Pierrotti, Lı́gia Camera; Caramori, Marlova Luzzi; Azevedo, Luiz Sergio; Ibrahim, Karim Yaqub; Dulley, Frederico Luiz; Varkulja, Glaucia Fernanda; Castro, Gilberto de; Almeida, Guilherme Silva de; Marques, Heloísa Helena de Souza; Shikanai-Yasuda, Maria Aparecida

doi:10.6061/clinics/2012(06)23

Cited by 1 publication

(2 citation statements)

References 30 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A clear need exists to delineate best practices in antifungal prophylaxis with attention to the incidence, timing, and mortality associated with IFI, particularly Candida and invasive aspergillosis. A superior strategy is difficult to discern . In general, routine antifungal prophylaxis in heart transplant recipients is not recommended .…”

Section: Discussionmentioning

confidence: 99%

“…A superior strategy is difficult to discern . In general, routine antifungal prophylaxis in heart transplant recipients is not recommended . One proposed strategy has been to target prophylaxis according to risk, defined by re‐operation, CMV infection, post‐transplant hemodialysis, and the occurrence of an episode of invasive aspergillosis at the transplant center within 2 months of the transplant procedure .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Invasive fungal infection after heart transplantation: A 7‐year, single‐center experience

Echenique

Angarone

Gordon

et al. 2017

Transplant Infectious Dis

View full text Add to dashboard Cite

The cumulative incidence was 10.7%. IFIs were associated with pre- and post-HT vancomycin-resistant Enterococcus colonization and/or infection, post-HT renal replacement therapy, anti-thymocyte globulin induction, and antibody-mediated rejection. There were no associations with diabetes mellitus, desensitization, 2R/3R cellular rejection, treatments for rejection, re-operation, neutropenia, or cytomegalovirus infection. IFIs were associated with death (P=.02, OR 3.9, 95% CI 1.3-12.1) and 1-year mortality (P<.001, OR 9.0, 95% CI 2.3-35.7), but not 3-year mortality. Associations with Hispanic ethnicity must be validated. Optimal strategies for risk reduction and prophylaxis remain undefined.

show abstract

Section: Discussionmentioning

confidence: 99%